Overview
Disorders of the stomach encompass a range of conditions affecting gastric function, including but not limited to peptic ulcers, gastritis, functional dyspepsia, and hypersecretory states like Zollinger-Ellison syndrome. These conditions are clinically significant due to their impact on nutrient absorption, quality of life, and potential complications such as bleeding, perforation, and obstruction. They affect individuals across all age groups but are more prevalent in older adults and those with specific risk factors like Helicobacter pylori infection, NSAID use, and stress. Understanding these disorders is crucial in day-to-day practice for timely diagnosis and effective management to prevent complications and improve patient outcomes 26.Pathophysiology
The pathophysiology of stomach disorders varies depending on the specific condition. For instance, in Helicobacter pylori gastritis, the bacterium adheres to the gastric mucosa, triggering an inflammatory response that leads to mucosal damage and altered gastric acid secretion. This inflammation can progress to peptic ulcers when the protective mucosal barrier is compromised 2. In functional dyspepsia, the exact mechanisms are less clear but likely involve altered gastrointestinal motility, visceral hypersensitivity, and psychosocial factors that disrupt normal gastric function without identifiable structural abnormalities 2. Additionally, hypersecretory states like Zollinger-Ellison syndrome, often associated with gastrinomas, result from excessive gastrin production, leading to hypergastrinemia and increased parietal cell activity, which in turn causes profound gastric acid hypersecretion 6. These diverse mechanisms underscore the need for tailored therapeutic approaches based on the underlying pathology 26.Epidemiology
The incidence and prevalence of stomach disorders vary widely. Helicobacter pylori infection, a leading cause of gastritis and peptic ulcers, affects approximately 30-50% of the global population, though only a fraction develop clinically significant disease 2. Peptic ulcer disease has a lifetime prevalence of around 10-15% in Western populations, with a higher incidence in older adults and those with chronic NSAID use 2. Functional dyspepsia is more common, affecting up to 30% of adults at some point, with a higher prevalence in women and individuals with psychological distress 2. Geographic variations exist, with higher rates of certain disorders noted in regions with poor sanitation and limited access to healthcare 2. Trends over time show a decline in peptic ulcer disease due to better infection control and pharmacological interventions, while functional dyspepsia rates remain relatively stable 2.Clinical Presentation
Patients with stomach disorders present with a spectrum of symptoms. Typical presentations include epigastric pain, nausea, vomiting, bloating, and early satiety, particularly in peptic ulcer disease and gastritis. Functional dyspepsia often manifests with persistent or recurrent indigestion without an identifiable organic cause. Red-flag symptoms such as significant weight loss, hematemesis, melena, or anemia suggest complications like bleeding ulcers or malignancy and warrant urgent evaluation 2. Additionally, severe or worsening symptoms, especially in older adults, should prompt thorough investigation to rule out serious underlying conditions 2.Diagnosis
The diagnostic approach for stomach disorders involves a combination of clinical assessment, laboratory tests, and endoscopic evaluation. Initial steps include a detailed history and physical examination to identify risk factors and symptom patterns. Key diagnostic criteria and tests include:Management
First-Line Treatment
Second-Line Treatment
Specialist Escalation
Contraindications:
Complications
Common complications include:Refer patients with severe or worsening symptoms, unexplained weight loss, or alarming signs like hematemesis to specialists promptly 2.
Prognosis & Follow-Up
The prognosis for stomach disorders varies widely based on the specific condition and timeliness of intervention. Successful eradication of Helicobacter pylori generally leads to resolution of gastritis and ulcers, with low recurrence rates if risk factors are managed. Functional dyspepsia often has a chronic course but can improve with lifestyle modifications and appropriate pharmacotherapy. Regular follow-up is crucial, typically every 3-6 months initially, to monitor symptom control and adjust treatment as needed. Prognostic indicators include response to initial therapy, absence of complications, and control of underlying risk factors 2.Special Populations
Key Recommendations
References
1 Aldrich JV, Kulkarni SS, Senadheera SN, Ross NC, Reilley KJ, Eans SO et al.. Unexpected opioid activity profiles of analogues of the novel peptide kappa opioid receptor ligand CJ-15,208. ChemMedChem 2011. link 2 Farrell JJ, Taupin D, Koh TJ, Chen D, Zhao CM, Podolsky DK et al.. TFF2/SP-deficient mice show decreased gastric proliferation, increased acid secretion, and increased susceptibility to NSAID injury. The Journal of clinical investigation 2002. link 3 Jin R, Yu H, Liu Z, Zhang X, Qu Y. Design and characterization of β-cyclodextrin-encapsulated walnut peptide-calcium-zinc chelates: physical characteristics, bitterness masking, stability, and sustained release. Food chemistry 2026. link 4 Sato T, Nyborg AC, Iwata N, Diehl TS, Saido TC, Golde TE et al.. Signal peptide peptidase: biochemical properties and modulation by nonsteroidal antiinflammatory drugs. Biochemistry 2006. link 5 Duggan AW, Schaible HG, Hope PJ, Lang CW. Effect of peptidase inhibition on the pattern of intraspinally released immunoreactive substance P detected with antibody microprobes. Brain research 1992. link90059-i) 6 Guglietta A, Irons BJ, Lazarus LH. Effect of bombesin, dermorphin and salmon calcitonin on gastric acid secretion in rats. Methods and findings in experimental and clinical pharmacology 1988. link